Skip to main content
Erschienen in: World Journal of Urology 12/2020

18.02.2020 | Original Article

The association between N-methylnaltrexone, a peripherally acting mu-opioid receptor antagonist, and clinical outcomes in patients undergoing robotic-assisted radical cystectomy

verfasst von: Andrew T. Lenis, Vishnukamal Golla, Patrick M. Lec, David C. Johnson, Izak Faiena, Carol Lee, Siamak Rahman, Karim Chamie

Erschienen in: World Journal of Urology | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To assess the impact of N-methylnaltrexone, a peripherally acting mu-opioid receptor antagonist, on the post-operative recovery of patients undergoing robotic-assisted radical cystectomy for bladder cancer.

Methods

We retrospectively reviewed patients undergoing robotic-assisted radical cystectomy by a single surgeon (KC) prior to (control group) and after (treatment group) the routine use of N-methylnaltrexone. Kaplan–Meier curves and the log-rank test were used to quantify time to flatus, bowel movement, and discharge. Daily mean opioid use, daily pain assessment rating, and episodes of severe pain (7–10/10) were compared. Gastrointestinal-related complications, including ileus, emesis, and/or need for post-op nasogastric tube placement, and 30-day readmissions were also compared between groups. Charge capture data were compared between groups to analyze cost impact.

Results

29 patients each in the control and treatment group met inclusion criteria. Patients receiving N-methylnaltrexone had reduced length of stay compared with no N-methylnaltrexone (median 4 vs. 7 days, p < 0.01). Time to flatus and bowel movement, however, were similar. In a multivariable analysis controlling for possible confounders, however, the improvement in length of stay associated with N-methylnaltrexone use did not reach statistical significance (p = 0.11). Episodes of severe pain and composite gastrointestinal-related complications were reduced in the N-methylnaltrexone group (44.8% vs. 10.3%, p < 0.01). The reduction in length of stay was associated with approximately $10,500 in cost savings per patient.

Conclusions

In this study, N-methylnaltrexone was associated with reduced length of stay, fewer episodes of severe pain, and reduced costs. These results provide the impetus for further study.
Literatur
1.
Zurück zum Zitat Chang SAMS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR et al (2016) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol 196:1021–1029CrossRef Chang SAMS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR et al (2016) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol 196:1021–1029CrossRef
2.
Zurück zum Zitat Chang SAMS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP et al (2017) Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. J Urol 198:552–559CrossRef Chang SAMS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP et al (2017) Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. J Urol 198:552–559CrossRef
3.
Zurück zum Zitat Hu M, Jacobs BL, Montgomery JS, He C, Ye J, Zhang Y et al (2014) Sharpening the focus on causes and timing of readmission after radical cystectomy for bladder cancer—PubMed-NCBI. Cancer 120:1409–1416CrossRef Hu M, Jacobs BL, Montgomery JS, He C, Ye J, Zhang Y et al (2014) Sharpening the focus on causes and timing of readmission after radical cystectomy for bladder cancer—PubMed-NCBI. Cancer 120:1409–1416CrossRef
4.
Zurück zum Zitat Stitzenberg KB, Chang Y, Smith AB, Nielsen ME (2015) Exploring the burden of inpatient readmissions after major cancer surgery—PubMed-NCBI. J Clin Oncol. 33:455–464CrossRef Stitzenberg KB, Chang Y, Smith AB, Nielsen ME (2015) Exploring the burden of inpatient readmissions after major cancer surgery—PubMed-NCBI. J Clin Oncol. 33:455–464CrossRef
5.
Zurück zum Zitat Shabsigh A, Korets R, Vora KC, Brooks CM, Cronin AM, Savage C et al (2009) Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology—PubMed-NCBI. Eur Urol. 55:164–176CrossRef Shabsigh A, Korets R, Vora KC, Brooks CM, Cronin AM, Savage C et al (2009) Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology—PubMed-NCBI. Eur Urol. 55:164–176CrossRef
6.
Zurück zum Zitat Johar RS, Hayn MH, Stegemann AP, Ahmed K, Agarwal P, Balbay MD et al (2013) Complications after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium—PubMed-NCBI. Eur Urol. 64:52–57CrossRef Johar RS, Hayn MH, Stegemann AP, Ahmed K, Agarwal P, Balbay MD et al (2013) Complications after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium—PubMed-NCBI. Eur Urol. 64:52–57CrossRef
7.
Zurück zum Zitat Bragg D, El-Sharkawy AM, Psaltis E, Maxwell-Armstrong CA, Lobo DN (2015) Postoperative ileus: recent developments in pathophysiology and management. Clin Nutr 34:367–376CrossRef Bragg D, El-Sharkawy AM, Psaltis E, Maxwell-Armstrong CA, Lobo DN (2015) Postoperative ileus: recent developments in pathophysiology and management. Clin Nutr 34:367–376CrossRef
8.
Zurück zum Zitat Azhar RA, Bochner B, Catto J, Goh AC, Kelly J, Patel HD et al (2016) Enhanced recovery after urological surgery: a contemporary systematic review of outcomes, key elements, and research needs. Eur Urol 70:176–187CrossRef Azhar RA, Bochner B, Catto J, Goh AC, Kelly J, Patel HD et al (2016) Enhanced recovery after urological surgery: a contemporary systematic review of outcomes, key elements, and research needs. Eur Urol 70:176–187CrossRef
9.
Zurück zum Zitat Schwenk ES, Grant AE, Torjman MC, McNulty SE, Baratta JL, Viscusi ER (2017) The efficacy of peripheral opioid antagonists in opioid-induced constipation and postoperative ileus: a systematic review of the literature—PubMed-NCBI. Reg Anesth Pain Med. 42:767–777CrossRef Schwenk ES, Grant AE, Torjman MC, McNulty SE, Baratta JL, Viscusi ER (2017) The efficacy of peripheral opioid antagonists in opioid-induced constipation and postoperative ileus: a systematic review of the literature—PubMed-NCBI. Reg Anesth Pain Med. 42:767–777CrossRef
11.
Zurück zum Zitat Kauf TL, Svatek RS, Amiel G, Beard TL, CHANG SAMS, Fergany A et al (2014) Alvimopan, a peripherally acting μ-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: economic analysis of a phase 4 randomized, controlled trial. J Urol 191:1721–1727 Kauf TL, Svatek RS, Amiel G, Beard TL, CHANG SAMS, Fergany A et al (2014) Alvimopan, a peripherally acting μ-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: economic analysis of a phase 4 randomized, controlled trial. J Urol 191:1721–1727
12.
Zurück zum Zitat Yu CS, Chun H-K, Stambler N, Carpenito J, Schulman S, Tzanis E et al (2011) Safety and efficacy of methylnaltrexone in shortening the duration of postoperative ileus following segmental colectomy: results of two randomized—PubMed-NCBI. Dis Colon Rectum. 54:570–578CrossRef Yu CS, Chun H-K, Stambler N, Carpenito J, Schulman S, Tzanis E et al (2011) Safety and efficacy of methylnaltrexone in shortening the duration of postoperative ileus following segmental colectomy: results of two randomized—PubMed-NCBI. Dis Colon Rectum. 54:570–578CrossRef
13.
Zurück zum Zitat Viscusi ER, Rathmell JP, Fichera A, Binderow SR, Israel RJ, Galasso FL et al (2012) Randomized placebo-controlled study of intravenous methylnaltrexone in postoperative ileus—PubMed-NCBI. J Drug Assess. 2:127–134CrossRef Viscusi ER, Rathmell JP, Fichera A, Binderow SR, Israel RJ, Galasso FL et al (2012) Randomized placebo-controlled study of intravenous methylnaltrexone in postoperative ileus—PubMed-NCBI. J Drug Assess. 2:127–134CrossRef
14.
Zurück zum Zitat Belle JD, Pooli A, Oleynikov D, Deibert CM (2018) Alvimopan usage increasing following radical cystectomy. World J Urol 55:164–165 Belle JD, Pooli A, Oleynikov D, Deibert CM (2018) Alvimopan usage increasing following radical cystectomy. World J Urol 55:164–165
16.
Zurück zum Zitat Bochner BH, Dalbagni G, Sjoberg DD, Silberstein J, Paz GEK, Donat SM et al (2015) Comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: a randomized clinical trial—PubMed-NCBI. Eur Urol. 67:1042–1050CrossRef Bochner BH, Dalbagni G, Sjoberg DD, Silberstein J, Paz GEK, Donat SM et al (2015) Comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: a randomized clinical trial—PubMed-NCBI. Eur Urol. 67:1042–1050CrossRef
17.
Zurück zum Zitat Hanna N, Leow JJ, Sun M, Friedlander DF, Seisen T, Abdollah F et al (2018) Comparative effectiveness of robot-assisted vs. open radical cystectomy—PubMed-NCBI. Urol Oncol Semin Orig Investig. 36:88.e1–88.e9 Hanna N, Leow JJ, Sun M, Friedlander DF, Seisen T, Abdollah F et al (2018) Comparative effectiveness of robot-assisted vs. open radical cystectomy—PubMed-NCBI. Urol Oncol Semin Orig Investig. 36:88.e1–88.e9
18.
Zurück zum Zitat Son SK, Lee NR, Kang SH, Lee SH (2017) Safety and effectiveness of robot-assisted versus open radical cystectomy for bladder cancer: a systematic review and meta-analysis—PubMed-NCBI. J Laparoendosc Adv Surg Tech. 27:1109–1120CrossRef Son SK, Lee NR, Kang SH, Lee SH (2017) Safety and effectiveness of robot-assisted versus open radical cystectomy for bladder cancer: a systematic review and meta-analysis—PubMed-NCBI. J Laparoendosc Adv Surg Tech. 27:1109–1120CrossRef
21.
Zurück zum Zitat Kraft M, MacLaren R, Du W, Owens G (2010) Alvimopan (Entereg) for the management of postoperative ileus in patients undergoing bowel resection. P&T 35(1):44–49 Kraft M, MacLaren R, Du W, Owens G (2010) Alvimopan (Entereg) for the management of postoperative ileus in patients undergoing bowel resection. P&T 35(1):44–49
Metadaten
Titel
The association between N-methylnaltrexone, a peripherally acting mu-opioid receptor antagonist, and clinical outcomes in patients undergoing robotic-assisted radical cystectomy
verfasst von
Andrew T. Lenis
Vishnukamal Golla
Patrick M. Lec
David C. Johnson
Izak Faiena
Carol Lee
Siamak Rahman
Karim Chamie
Publikationsdatum
18.02.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 12/2020
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-020-03117-y

Weitere Artikel der Ausgabe 12/2020

World Journal of Urology 12/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.